Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seviteronel in CRPC progressing on enzalutamide or abiraterone
NCT02445976Phase 2Completed
- Sponsor
- Innocrin
- Start
- May 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of seviteronel in castration-resistant prostate cancer (CRPC), sponsored by Innocrin. Started May 2015; status: completed.
02
Drugs
seviteronel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02445976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445976.